CSPC Pharmaceutical Group Limited announced that the results from a first-in-human Phase I/II clinical study of SYS6090 (JMT108), an anti-programmed cell death receptor 1 (PD-1)/interleukin-15 (IL-15) ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results